Related references
Note: Only part of the references are listed.Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung
David R. Spigel et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis
V. R. Belum et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2016)
Incomplete target neutralization by the anti-cancer antibody rilotumumab
Sameer A. Greenall et al.
MABS (2016)
Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma
V. Finisguerra et al.
ONCOGENE (2016)
Challenges and opportunities for non-antibody scaffold drugs
Rodrigo Vazquez-Lombardi et al.
DRUG DISCOVERY TODAY (2015)
Onartuzumab in lung cancer: the fall of Icarus?
Christian Rolfo et al.
Expert Review of Anticancer Therapy (2015)
False-negative rate for HER2 testing in 738 gastric and gastroesophageal junction cancers (GEC) from two global randomized clinical trials
David Cunningham et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cabozantinib-Getting Under the Skin of Cutaneous Toxicity
Anuradha Jayaram et al.
JAMA ONCOLOGY (2015)
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications
Andreas Stahl et al.
ANGIOGENESIS (2013)
Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Charles J. Ryan et al.
CLINICAL CANCER RESEARCH (2013)
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET-Response
Paolo Michieli et al.
CLINICAL CANCER RESEARCH (2013)
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance
Arman Jahangiri et al.
CLINICAL CANCER RESEARCH (2013)
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Cristina Basilico et al.
CLINICAL CANCER RESEARCH (2013)
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
David C. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
Mark Merchant et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Efficient Tumor Targeting with High-Affinity Designed Ankyrin Repeat Proteins: Effects of Affinity and Molecular Size
Christian Zahnd et al.
CANCER RESEARCH (2010)
Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor-Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Michael S. Gordon et al.
CLINICAL CANCER RESEARCH (2010)
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Jie Ling et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Facile promoter deletion in Escherichia coli in response to leaky expression of very robust and benign proteins from common expression vectors
Martin Kawe et al.
MICROBIAL CELL FACTORIES (2009)
Receptor tyrosine kinase inhibitors in thyroid cancer
Maria Domenica Castellone et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Engineering novel binding proteins from nonimmunoglobulin domains
HK Binz et al.
NATURE BIOTECHNOLOGY (2005)
High-affinity binders selected from designed ankyrin repeat protein libraries
HK Binz et al.
NATURE BIOTECHNOLOGY (2004)
Designing repeat proteins:: Well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins
HK Binz et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Share Paper
